GoodRx (NasdaqGS:GDRX) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAubrey Reynolds - Director of Investor RelationsCameron Harbilas - Equity Research AssociateChris McGinnis - CFOJohn Ransom - Managing DirectorLaura Jensen - Chief Commercial Officer and President of Pharma DirectLisa Gill - Managing DirectorSteven Valiquette - Managing DirectorWendy Barnes - CEOConference Call ParticipantsAllen Lutz - Senior Equity Research AnalystDaniel Grosslight - Senior Research AnalystGeorge ...

GoodRx (NasdaqGS:GDRX) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAubrey Reynolds - Director of Investor RelationsCameron Harbilas - Equity Research AssociateChris McGinnis - CFOJohn Ransom - Managing DirectorLaura Jensen - Chief Commercial Officer and President of Pharma DirectLisa Gill - Managing DirectorSteven Valiquette - Managing DirectorWendy Barnes - CEOConference Call ParticipantsAllen Lutz - Senior Equity Research AnalystDaniel Grosslight - Senior Research AnalystGeorge ...

GoodRx (NasdaqGS:GDRX) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Speaker9Ladies and gentlemen, thank you for standing by, and welcome to the GoodRx fourth quarter and full year 2025 earnings call. As a reminder, today's conference is being recorded. I would like now to introduce your host for today's call, Aubrey Reynolds, Director of Investor Relations. Ms. Reynolds, you may begin.Speaker1Thank you, Operator. Good morning, everyone, and welcome to GoodRx's earnings conference call for the fourth ...

Core Insights - Hydreight Technologies Inc. reported a strong financial performance in Q2 2025, achieving a 31% year-over-year increase in GAAP revenue to $5.38 million and a topline revenue of $7.35 million, also up 31% compared to Q2 2024 [5][7] - The company has focused on expanding its modular VSDHOne platform, allowing customers to adopt services incrementally, and has prioritized strategic acquisitions to enhance margins and growth [1][3] - Hydreight has successfully entered new verticals such as genetic testing, anti-aging, and mental wellness, contributing to its growth strategy [3][5] Financial Performance - Q2 2025 GAAP revenue was $5.38 million, a 31% increase from Q2 2024, while topline revenue reached $7.35 million, also reflecting a 31% growth [5][7] - For the first six months of 2025, GAAP revenue totaled $9.92 million, up 33% year-over-year, with topline revenue at $13.88 million, also a 33% increase [5][7] - The company reported a gross margin of $1.93 million in Q2 2025, up from $1.56 million in Q2 2024, and an Adjusted EBITDA of $182K, indicating continued operational improvement [5][7] Strategic Initiatives - Hydreight has signed a binding letter of intent to acquire a 5% equity stake in Perfect Scripts, LLC, with an option to increase to 40%, establishing a strategic partnership [5][6] - The company has launched a personalized genetic testing and wellness solution on its VSDHOne platform, expanding its service offerings [6][5] - Hydreight is actively participating in investor conferences to enhance its visibility and attract new investors, with multiple events scheduled throughout 2025 [15][16] User Growth and Market Expansion - The company experienced approximately 77% growth in new nurse signups and a 48% increase in pharmacy orders compared to Q2 2024 [5][7] - The internal metrics for VSDHOne SKU orders indicated a strong demand, with approximately 42,829 pharmacy SKU orders received within the first 60 days of a targeted period [5][7] - Hydreight's platform has hosted over 3,000 nurses and 200 doctors, facilitating flexible at-home medical services across all 50 states in the U.S. [18][19]